Issue 24 - The Cancer Letter

Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.

SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.

LOGIN SUBSCRIBE NOW

SEARCH DATE

SEARCH TEXT

Cancel

OK

Cancel

OK

Delete Account

Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below

ARPA-H would launch 1,000 drugs, Eric Lander promises NIH advisors

Biden’s budget request for NCI would set back Sharpless’s goal of raising R01 paylines to 15%

Annals of Unintended Consequences: How FDA regulations undermine the biosimilar marketplace and the BPCIA

On the shoulders of giants: Research milestones and the Rabson-Kirschstein photo archive

The Cancer Letter receives 8 journalism, design awards

In Brief

Suresh S. Ramalingam named executive director of Winship Cancer Institute

John V. Cox receives ASCO’s 2021 Joseph V. Simone Award

Conquer Cancer names 2021 ASCO annual meeting Merit Award recipients

Conquer Cancer honors rising oncology professionals

Jazz Pharmaceuticals collaborates with lung cancer groups on digital hub for emotional, social and physical needs of SCLC community

ACCC launches Cancer Buzz TV

Funding Opportunities

DoD Kidney Cancer Research Program funding opportunities for FY21

Thermo Fisher Scientific opens submissions for the Oncomine Clinical Research Grant program

Clinical Roundup

PanCAN adds FibroGen’s drug as treatment arm to adaptive Precision Promise trial

Three studies reinforce efficacy of Venclexta combinations in CLL and AML

Yale Cancer Center study reveals new pathway for brain tumor therapy

Astronomy meets pathology to identify predictive biomarkers for cancer immunotherapy

“Bad fat” suppresses killer T cells from attacking cancer

Drugs & Targets

FDA approves Ayvakit for advanced systemic mastocytosis

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login